Karyopharm Therapeutics Inc. (NASDAQ:KPTI) released its quarterly earnings results on Tuesday. The company reported ($0.64) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.64), MarketWatch Earnings reports. Karyopharm Therapeutics had a negative net margin of 50,646.40% and a negative return on equity of 72.41%. During the same quarter last year, the company posted ($0.84) earnings per share. The firm’s revenue was down 95.0% compared to the same quarter last year.

Shares of Karyopharm Therapeutics (KPTI) traded up 5.19% on Tuesday, hitting $8.92. The company had a trading volume of 70,566 shares. Karyopharm Therapeutics has a 52 week low of $6.27 and a 52 week high of $14.63. The company’s market capitalization is $420.29 million. The stock’s 50-day moving average is $9.31 and its 200 day moving average is $10.11.

A number of hedge funds and other institutional investors have recently made changes to their positions in KPTI. Bank of America Corp DE boosted its position in shares of Karyopharm Therapeutics by 0.7% in the first quarter. Bank of America Corp DE now owns 46,127 shares of the company’s stock valued at $592,000 after buying an additional 308 shares in the last quarter. Metropolitan Life Insurance Co. NY boosted its position in shares of Karyopharm Therapeutics by 12.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 21,911 shares of the company’s stock valued at $206,000 after buying an additional 2,460 shares in the last quarter. American International Group Inc. boosted its position in shares of Karyopharm Therapeutics by 20.9% in the first quarter. American International Group Inc. now owns 16,422 shares of the company’s stock valued at $211,000 after buying an additional 2,836 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its position in shares of Karyopharm Therapeutics by 4.5% in the first quarter. Schwab Charles Investment Management Inc. now owns 86,514 shares of the company’s stock valued at $1,111,000 after buying an additional 3,762 shares in the last quarter. Finally, C WorldWide Group Holding A S boosted its position in shares of Karyopharm Therapeutics by 30.2% in the first quarter. C WorldWide Group Holding A S now owns 16,928 shares of the company’s stock valued at $217,000 after buying an additional 3,928 shares in the last quarter. Institutional investors own 57.46% of the company’s stock.

A number of brokerages recently issued reports on KPTI. Cantor Fitzgerald reiterated an “overweight” rating and set a $18.00 price objective on shares of Karyopharm Therapeutics in a research note on Monday, May 15th. ValuEngine downgraded Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, May 25th. Robert W. Baird reiterated an “outperform” rating and set a $15.00 price objective on shares of Karyopharm Therapeutics in a research note on Tuesday, July 4th. Zacks Investment Research upgraded Karyopharm Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a research note on Thursday, July 6th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $16.00 price objective on shares of Karyopharm Therapeutics in a research note on Friday, July 14th. Two analysts have rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $14.46.

TRADEMARK VIOLATION WARNING: “Karyopharm Therapeutics Inc. (KPTI) Posts Quarterly Earnings Results, Hits Expectations” was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/08/08/karyopharm-therapeutics-inc-kpti-releases-quarterly-earnings-results.html.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Earnings History for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.